Tag Archives: infectious disease

Post-Con BIO CEO Company Snapshot: Immunovaccine

Immunovaccine-logo-PMS

A few weeks ago, the BIO CEO & Investor Conference concluded in New York City. With a 30% increase in One-on-One Partnering meetings and sold out company presentations, industry execs gathered to do business, and hear the latest from innovative companies. As a precursor to the event, the company snapshot campaign highlighted a few of the companies who would be participating onsite. This year, the snapshot feature concludes with an interview from Marc Mansour, Ph.D., Chief Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , ,

BIO Investor Forum Company Snapshot: Vaccinex

Vaccinex

Recently, the CEO of Prosensa provided their company’s perspective participating in last year’s BIO Investor Forum. Looking ahead at this year’s event, we spoke to the President & CEO of Vaccinex, Dr. Maurice Zauderer. They will be presenting in the regular private track, which features later-stage private companies. Read below to learn more about this biotech.   Company Snapshot What is your company’s lead product or technology? Vaccinex’s lead product, VX15, is an antibody to semaphorin Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

#BIF2012 Company Snapshot: Chimerix

Chimerix

Our next Company Snapshot for next week’s BIO Investor Forum is Chimerix. They will be presenting on Tuesday, at 1:30pm, and will also be participating in a panel at the event, Choose Your Own Adventure — Late Stage Private Company Decisions on Wednesday. To learn more about the company before you get onsite, continue reading! Company Snapshot What is your company’s lead product or technology? Chimerix’s lead product is CMX001, a novel, broad-spectrum, oral antiviral that inhibits double-stranded Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , ,

#BIF2012 Company Snapshot: ContraFect Corporation

ContraFect

The BIO Investor Forum is fast approaching! Below you’ll find our first Company Snapshot of one of the event’s presenting companies, ContraFect Corporation. Continue reading to learn more about ContraFect’s product, their strategies, and what you can expect from their company in the coming months. Company Snapshot What is your company’s lead product or technology? ContraFect is a private company developing biotherapeutics for resistant, life threatening infections. Our lead compound, CF-301, is a bacteriophage lysin, Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO Investor Forum Company Snapshot: Immune Design

immunedesign

In the third installment of the Investor Forum Company Snapshots, hear from Immune Design Corp. The CEO of the company, Dr. Carlos Paya, will be presenting next week at the 10th Annual BIO Investor Forum on Tuesday afternoon. Company Snapshot What are the short-term and long-term priorities for your company? Short term: focus on validating in patients a product from each of our two novel technologies.  We will be conducting testing of : 1) An Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,